Results 191 to 200 of about 3,819 (202)

Performance of idarucizumab as antidote of dabigatran in daily clinical practice

Europace, 2019
Sake J Van Der Wall, Nienke van Rein, Bartholomeus Jf Van Den Bemt   +2 more
exaly  

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Thrombosis and Haemostasis, 2015
Stephan Glund
exaly  

Idarucizumab for the Reversal of Dabigatran

Annals of Emergency Medicine, 2017
Michael, Gottlieb, Basem, Khishfe
openaire   +2 more sources

The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran

Journal of Thrombosis and Haemostasis, 2017
Cihan Ay
exaly  

Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR)

Journal of Neurology, 2019
Clemens Küpper, Katharina Feil, Matthias Klein   +2 more
exaly  

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab

Thrombosis and Haemostasis, 2015
Oliver Grottke
exaly  

Concerns about idarucizumab for dabigatran reversal

Blood Coagulation & Fibrinolysis, 2016
Claudia, Stöllberger, Peter, Pommer, Birke, Schneider, Josef, Finsterer   +3 more
openaire   +2 more sources

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran

Journal of Thrombosis and Haemostasis, 2019
Stephan Glund
exaly  

Dabigatran-etexilate/idarucizumab

Reactions Weekly, 2018
openaire   +1 more source

Dabigatran etexilate/idarucizumab interaction

Reactions Weekly, 2018
openaire   +2 more sources